MUMPS
MCID: MMP001
MIFTS: 59

Mumps (MUMPS)

Categories: Ear diseases, Endocrine diseases, Infectious diseases, Oral diseases, Rare diseases

Aliases & Classifications for Mumps

MalaCards integrated aliases for Mumps:

Name: Mumps 12 76 53 55 43 3 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:10264
ICD10 33 B26 B26.9 B26.8
ICD9CM 35 072
MeSH 44 D009107
NCIt 50 C29888
SNOMED-CT 68 36989005
UMLS 73 C0026780

Summaries for Mumps

MedlinePlus : 43 Mumps is an illness caused by the mumps virus. It starts with Fever Headache Muscle aches Tiredness Loss of appetite After that, the salivary glands under the ears or jaw become swollen and tender. The swelling can be on one or both sides of the face. Symptoms last 7 to 10 days. Serious complications are rare. You can catch mumps by being with another person who has it. There is no treatment for mumps, but the measles-mumps-rubella (MMR) vaccine can prevent it. Before the routine vaccination program in the United States, mumps was a common illness in infants, children and young adults. Now it is a rare disease in the U.S. Centers for Disease Control and Prevention

MalaCards based summary : Mumps is related to primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection and measles, and has symptoms including fever and pruritus. An important gene associated with Mumps is STAT2 (Signal Transducer And Activator Of Transcription 2), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Immunologic Factors and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, heart and testes, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A viral infectious disease that results in inflammation located in salivary gland, has material basis in Mumps virus, which is transmitted by droplet spread of saliva or mucus from the mouth, nose, or throat of an infected person, or transmitted by contaminated fomites. The infection has symptom fever, has symptom headache, has symptom muscle aches, has symptom tiredness, has symptom loss of appetite, has symptom swollen and tender salivary glands under the ears or jaw on one or both sides of the face.

CDC : 3 Mumps is a contagious disease caused by a virus. It typically starts with a few days of fever, headache, muscle aches, tiredness, and loss of appetite, followed by swollen salivary glands. You can protect yourself and your family against mumps with vaccination.

Wikipedia : 76 Mumps is a viral disease caused by the mumps virus. Initial signs and symptoms often include fever,... more...

Related Diseases for Mumps

Diseases in the Mumps family:

Congenital Mumps

Diseases related to Mumps via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 303)
# Related Disease Score Top Affiliating Genes
1 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 33.6 IFNAR2 STAT2
2 measles 32.1 STAT2 STAT1 IL2 IFNG IFNAR2 CD46
3 rubella 31.7 TNF IL12RB2 IL10RB IFNAR2 HLA-DRB1 HLA-DPB1
4 viral infectious disease 30.3 IFNG IL2 STAT1 TNF
5 tetanus 30.2 IFNG IL2 IL2RA
6 hepatitis b 30.0 IFNAR2 IFNG IL10RB TNF
7 recurrent respiratory papillomatosis 29.8 HLA-DRB1 IL2
8 uveitis 29.7 IFNG IL2RA TNF
9 scleritis 29.6 IFNG TNF
10 erythema multiforme 29.4 IFNG IL2 TNF
11 hematopoietic stem cell transplantation 29.4 IFNG IL2 TNF
12 pleurisy 29.4 IFNG IL2 TNF
13 human immunodeficiency virus infectious disease 29.4 IFNG IL2 TNF
14 rheumatic disease 29.3 TNF IL2RA IFNG HLA-DRB1
15 asthma 29.2 HLA-DPB1 HLA-DRB1 IFNG IL2RA TNF
16 human immunodeficiency virus type 1 29.2 IFNG IL2 STAT1 TNF
17 posterior uveitis 29.1 TNF IL2RA IL2 IFNG
18 diabetes mellitus 28.9 HLA-DPB1 HLA-DRB1 IFNG IL2 IL2RA TNF
19 multiple sclerosis 28.7 TNFRSF1A TNF STAT1 IL2RA IL2 IFNG
20 inflammatory bowel disease 28.6 TNFRSF1A TNF STAT1 IL2 IL12RB2 IL10RB
21 rheumatoid arthritis 28.6 TNFRSF1A TNF IL2RA IL2 IFNG HLA-DRB1
22 congenital mumps 12.2
23 acute disseminated encephalomyelitis 11.5
24 acute pancreatitis 11.3
25 endotheliitis 11.3
26 testicular microlithiasis 11.0
27 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 11.0
28 immunodeficiency 45 11.0
29 male infertility 11.0
30 salivary gland disease 11.0
31 immune-mediated encephalomyelitis 11.0
32 postinfectious encephalomyelitis 11.0
33 orchitis 10.7
34 meningitis 10.5
35 aseptic meningitis 10.4
36 parotitis 10.4
37 chickenpox 10.4
38 encephalitis 10.4
39 meningoencephalitis 10.3
40 hepatitis 10.3
41 pertussis 10.3
42 autism 10.2
43 hydrocephalus 10.2
44 diphtheria 10.2
45 influenza 10.2
46 marburg hemorrhagic fever 10.2 STAT2 TNF
47 microscopic polyangiitis 10.2 HLA-DRB1 TNF
48 chronic gonococcal salpingitis 10.2 TNF TNFRSF1A
49 endocardial fibroelastosis 10.2
50 pancreatitis 10.2

Graphical network of the top 20 diseases related to Mumps:



Diseases related to Mumps

Symptoms & Phenotypes for Mumps

UMLS symptoms related to Mumps:


fever, pruritus

GenomeRNAi Phenotypes related to Mumps according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 IL2 IL2RA RIPK1 STAT1 TNF TNFRSF1A
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 IL2 IL2RA RIPK1 STAT1 TNF TNFRSF1A

MGI Mouse Phenotypes related to Mumps:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 IFNAR2 IFNG IL10RB IL12RB2 IL2 IL2RA
2 immune system MP:0005387 10.13 IFNAR2 IFNG IL10RB IL12RB2 IL2 IL2RA
3 digestive/alimentary MP:0005381 10.09 IFNG IL10RB IL12RB2 IL2 IL2RA RIPK1
4 endocrine/exocrine gland MP:0005379 10.06 IFNG IL10RB IL12RB2 IL2 IL2RA RIPK1
5 mortality/aging MP:0010768 9.93 IFNAR2 IFNG IL10RB IL2 IL2RA IRAK1
6 liver/biliary system MP:0005370 9.86 IFNG IL10RB IL12RB2 IL2 RIPK1 STAT1
7 neoplasm MP:0002006 9.5 IFNAR2 IFNG IL12RB2 IL2 STAT1 TNF
8 vision/eye MP:0005391 9.17 CD46 IFNG IL2 IL2RA STAT1 TNF

Drugs & Therapeutics for Mumps

Drugs for Mumps (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 78)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
2 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
3 Liver Extracts Phase 4
4 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
7 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Not Applicable
8
Tetracycline Approved, Vet_approved Phase 3,Phase 1,Phase 2 60-54-8 5353990
9
Aluminum hydroxide Approved, Investigational Phase 3,Phase 2 21645-51-2
10
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 44475014
11
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
12
Lactitol Investigational Phase 3,Phase 2 585-86-4 3871
13
Cobalamin Experimental Phase 3 13408-78-1 6438156
14 Hemagglutinins Phase 3
15 taxane Phase 3,Not Applicable
16 Somatomedin B Phase 3
17 Anti-Infective Agents Phase 3,Phase 1,Phase 2
18 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
19 Vitamin B 12 Phase 3
20 Vitamin B12 Phase 3
21 PENTA Phase 3,Phase 2
22
Altretamine Approved Phase 2 645-05-6 2123
23
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
24
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
25
Obinutuzumab Approved, Investigational Phase 2,Phase 1 949142-50-1
26
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
27
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
28
Mycophenolic acid Approved Phase 2 24280-93-1 446541
29
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
30
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
31
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
32
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
33 Anticoagulants Phase 2
34 Fibrinolytic Agents Phase 2
35 Immunoglobulin G Phase 2
36 Antibodies, Monoclonal Phase 2,Not Applicable
37 Interleukin-2 Phase 2
38 Immunosuppressive Agents Phase 2,Not Applicable
39 Antineoplastic Agents, Phytogenic Phase 2
40 Antimitotic Agents Phase 2
41 Albumin-Bound Paclitaxel Phase 2
42 Peripheral Nervous System Agents Phase 2
43 Hormone Antagonists Phase 2
44 Antineoplastic Agents, Hormonal Phase 2
45 Prednisolone acetate Phase 2
46 Antiemetics Phase 2
47 Methylprednisolone acetate Phase 2
48 Neuroprotective Agents Phase 2
49 Anti-Inflammatory Agents Phase 2
50 glucocorticoids Phase 2

Interventional clinical trials:

(show top 50) (show all 151)
# Name Status NCT ID Phase Drugs
1 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
2 Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients Unknown status NCT01770119 Phase 4
3 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
4 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
5 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
6 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
7 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR Completed NCT02325310 Phase 4
8 Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Completed NCT03160820 Phase 4
9 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
10 MMR Vaccination Among HIV-infected Adults Completed NCT02724852 Phase 4
11 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
12 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
13 Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
14 Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children Completed NCT02253407 Phase 4
15 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
16 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
17 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
18 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines Recruiting NCT03368495 Phase 4
19 Homeopathic Vaccine Trial Recruiting NCT02825368 Phase 4
20 MMR at 6 Months Trial Not yet recruiting NCT03780179 Phase 4
21 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Not yet recruiting NCT03350698 Phase 4
22 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
23 Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants Completed NCT02692599 Phase 3
24 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3
25 A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED) Completed NCT00092391 Phase 3
26 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127023 Phase 3
27 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127010 Phase 3
28 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
29 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed NCT01536405 Phase 3
30 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed NCT01681992 Phase 3
31 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
32 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
33 Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Completed NCT00092430 Phase 3
34 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
35 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Completed NCT01621802 Phase 3
36 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) Completed NCT00432042 Phase 3
37 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Completed NCT01702428 Phase 3
38 Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children Completed NCT00192491 Phase 3
39 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed NCT01506193 Phase 3
40 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed NCT00969436 Phase 3
41 Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children Completed NCT00197015 Phase 3
42 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) Completed NCT00975507 Phase 3
43 Safety Study of ProQuad® rHA in Infants (V221-037) Completed NCT00560755 Phase 3
44 Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Completed NCT00226499 Phase 3
45 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers Completed NCT00422292 Phase 3
46 A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) Completed NCT00985166 Phase 3
47 Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine Completed NCT00406211 Phase 3
48 Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) Completed NCT00985153 Phase 3
49 ProQuad® Intramuscular vs Subcutaneous Completed NCT00402831 Phase 3
50 Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Completed NCT00566527 Phase 3

Search NIH Clinical Center for Mumps

Cochrane evidence based reviews: mumps

Genetic Tests for Mumps

Anatomical Context for Mumps

MalaCards organs/tissues related to Mumps:

41
Salivary Gland, Heart, Testes, T Cells, Liver, Myeloid, Thyroid

Publications for Mumps

Articles related to Mumps:

(show top 50) (show all 1289)
# Title Authors Year
1
Therapeutic Outcome of Intralesional Immunotherapy in Cutaneous Warts Using the Mumps, Measles, and Rubella Vaccine: A Randomized, Placebo-controlled Trial. ( 29785233 )
2018
2
Knowledge gaps persist and hinder progress in eliminating mumps. ( 29784466 )
2018
3
Genomic non-coding regions reveal hidden patterns of mumps virus circulation in Spain, 2005 to 2015. ( 29667574 )
2018
4
Mumps: A Pain in the Neck. ( 29718326 )
2018
5
Assessment of mumps-containing vaccine effectiveness during an outbreak: Importance to introduce the 2-dose schedule for China. ( 29377772 )
2018
6
Impact of meteorological factors on mumps and potential effect modifiers: An analysis of 10 cities in Guangxi, Southern China. ( 29966878 )
2018
7
Resurgence risk for measles, mumps and rubella in France in 2018 and 2020. ( 29945697 )
2018
8
Non-mumps Viral Parotitis During the 2014-2015 Influenza Season in the United States. ( 29617951 )
2018
9
Prevalence of Inadequate Immunity to Measles, Mumps, Rubella, and Varicella in MLB and NBA Athletes. ( 29792776 )
2018
10
Utility of neutralization test for the laboratory diagnosis of suspected mumps cases. ( 29363797 )
2018
11
Mumps disease in Beijing in the era of two-dose vaccination policy, 2005-2016. ( 29653850 )
2018
12
Recognizing Measles, Mumps, and Rubella in the Emergency Department. ( 29715253 )
2018
13
Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination. ( 29253144 )
2018
14
An outbreak due to mumps virus genotype G in a tribal population during 2016-17 from India. ( 29873412 )
2018
15
Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7A years of age or older: a phaseA III, randomized study. ( 29902133 )
2018
16
Application of a mixture model to assess the effect of measles-mumps-rubella vaccine on the mumps epidemic in children from kindergarten to early school age in Jiangsu Province, China. ( 29792546 )
2018
17
Pharyngolaryngeal edema in mumps virus infection: Rare complication. ( 29878635 )
2018
18
Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial. ( 29395526 )
2018
19
Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. ( 29317117 )
2018
20
Mumps outbreaks: A problem in need of solutions. ( 29678496 )
2018
21
Meteorological factors and the incidence of mumps in Fujian Province, China, 2005-2013: Non-linear effects. ( 29734606 )
2018
22
Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak. ( 29324728 )
2018
23
Acute Motor Axonal Polyneuropathy Following Mumps Infection in a 9-Year-Old Girl. ( 29669036 )
2018
24
Reply to "Implementation of molecular techniques for diagnosis of mumps". ( 29891344 )
2018
25
Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. ( 29426830 )
2018
26
Implementation of molecular techniques for diagnosis of mumps. ( 29789179 )
2018
27
Mumps infection but not childhood vaccination induces persistent polyfunctional CD8<sup>+</sup>T-cell memory. ( 29339261 )
2018
28
Laboratory testing and phylogenetic analysis during a mumps outbreak in Ontario, Canada. ( 29866178 )
2018
29
Assessment of Humoral Immunity to Hepatitis B, Measles, Rubella, and Mumps in Children After Chemotherapy. ( 29309372 )
2018
30
Revaccination with Measles-mumps-rubella Vaccine and Infectious Disease Morbidity: A Danish Register-based Cohort Study. ( 29846533 )
2018
31
Granulomatosis With Polyangiitis Associated With Mumps Viral Infection. ( 29424761 )
2018
32
Immunity against measles, mumps, rubella, varicella, diphtheria, tetanus, polio, hepatitis A and hepatitis B among adult asylum seekers in the Netherlands, 2016. ( 29454516 )
2018
33
A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. ( 29576304 )
2018
34
Seroprevalence of Maternal and Cord Antibodies Specific for Diphtheria, Tetanus, Pertussis, Measles, Mumps and Rubella in Shunyi, Beijing. ( 30158679 )
2018
35
Active immunization status against measles, mumps, rubella, hepatitis B in internationally adopted children, surveyed at the university hospital of Palermo, Sicily. ( 30062371 )
2018
36
Immunosuppression Does Not Affect Antibody Concentrations to Measles, Mumps, and Rubella in Patients with Inflammatory Bowel Disease. ( 30317494 )
2018
37
Atypical Kawasaki Disease in a 4 Years Old Child with Mumps. ( 30387476 )
2018
38
Mass spectrometry-based investigation of measles and mumps virus proteome. ( 30326905 )
2018
39
To the editor: Response to Willame, et al., published in Vaccine 35 (2017) 5551-5558, entitled "Pain caused by measles, mumps, and rubella vaccines: A systematic literature review". ( 30348361 )
2018
40
Reply to Lee et al.'s letter to the editor pertaining to our publication entitled "Pain caused by measles, mumps, and rubella vaccines: A systematic literature review". ( 30348362 )
2018
41
Perspectives on the Measles, Mumps and Rubella Vaccination among Somali Mothers in Stockholm. ( 30388799 )
2018
42
Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age. ( 30481110 )
2018
43
Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial. ( 30104117 )
2018
44
Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults. ( 30107992 )
2018
45
What are the beliefs and perceptions of practice nurses' influence about the uptake of the measles, mumps, and rubella vaccine?: An integrative literature review. ( 30109727 )
2018
46
Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study. ( 30118386 )
2018
47
Impact of history of febrile convulsions on the risk difference of febrile convulsions with the tetravalent measles-mumps-rubella-varicella vaccine: Post-hoc exploratory analysis of results from a matched-cohort study. ( 30131195 )
2018
48
Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation. ( 30171797 )
2018
49
Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection. ( 30209129 )
2018
50
Cost of Public Health Response and Outbreak Control With a Third Dose of Measles-Mumps-Rubella Vaccine During a University Mumps Outbreak-Iowa, 2015-2016. ( 30302350 )
2018

Variations for Mumps

Expression for Mumps

Search GEO for disease gene expression data for Mumps.

Pathways for Mumps

Pathways related to Mumps according to GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 CD46 HLA-DPB1 HLA-DRB1 IFNAR2 IFNG IL10RB
2
Show member pathways
13.88 IFNAR2 IL2 IL2RA IRF2 RIPK1 STAT1
3
Show member pathways
13.87 IL10RB IL12RB2 IL2 IL2RA IRAK1 RIPK1
4
Show member pathways
13.69 IFNAR2 IFNG IL10RB IL12RB2 IL2 IL2RA
5
Show member pathways
13.58 IFNAR2 IFNG IL10RB IL12RB2 IL2 IL2RA
6
Show member pathways
13.47 IL10RB IL12RB2 IL2 IL2RA IRAK1 RIPK1
7
Show member pathways
13.3 IL10RB IL12RB2 IL2 IL2RA TNF TNFRSF1A
8
Show member pathways
13.28 HLA-DRB1 IFNG IL2 IL2RA IRAK1 STAT1
9
Show member pathways
13.14 IFNAR2 IL10RB IRAK1 RIPK1 STAT1 STAT2
10
Show member pathways
13.11 HLA-DPB1 HLA-DRB1 IFNAR2 IFNG IL10RB IL12RB2
11
Show member pathways
13.06 IFNAR2 IL2 IL2RA STAT1 STAT2 TNF
12
Show member pathways
13.06 IFNAR2 IFNG IL2 IRAK1 RIPK1 STAT1
13 12.93 IFNAR2 IFNG IL12RB2 IL2 IL2RA STAT1
14
Show member pathways
12.85 HLA-DPB1 HLA-DRB1 IFNAR2 IFNG IL10RB IL12RB2
15
Show member pathways
12.84 IRAK1 IRF2 RIPK1 TNF TNFRSF1A
16
Show member pathways
12.81 IL2 IL2RA STAT1 TNF TNFRSF1A
17
Show member pathways
12.74 IL2 IRAK1 RIPK1 TNF TNFRSF1A
18
Show member pathways
12.72 IFNG RIPK1 STAT1 TNF TNFRSF1A
19
Show member pathways
12.68 IFNG IL10RB IL2 RIPK1 STAT1 TNF
20
Show member pathways
12.67 HLA-DPB1 HLA-DRB1 IFNG IL10RB IL12RB2 IL2
21
Show member pathways
12.63 HLA-DPB1 HLA-DRB1 IFNAR2 IFNG IRF2 STAT1
22
Show member pathways
12.58 HLA-DPB1 HLA-DRB1 IFNAR2 IFNG IL10RB IL12RB2
23 12.54 HLA-DPB1 HLA-DRB1 IL2 IL2RA TNF TNFRSF1A
24
Show member pathways
12.53 IFNAR2 IFNG IL2 TNF
25
Show member pathways
12.49 IFNAR2 IFNG IL10RB IL12RB2 IL2 IL2RA
26
Show member pathways
12.42 CD46 HLA-DPB1 HLA-DRB1 IFNAR2 IFNG IL2
27 12.4 HLA-DPB1 HLA-DRB1 IFNAR2 IRAK1 RIPK1 STAT1
28
Show member pathways
12.37 RIPK1 STAT1 TNF TNFRSF1A
29
Show member pathways
12.36 IFNAR2 IFNG IL2 IL2RA IRF2 STAT1
30
Show member pathways
12.34 IFNG IRAK1 STAT1 TNF
31
Show member pathways
12.34 IFNAR2 IFNG STAT1 STAT2
32
Show member pathways
12.33 HLA-DPB1 HLA-DRB1 IFNG IL10RB IRAK1 STAT1
33
Show member pathways
12.32 IFNAR2 IFNG RIPK1 STAT1 STAT2 TNF
34 12.26 HLA-DPB1 HLA-DRB1 IFNG IL10RB IRAK1 STAT1
35
Show member pathways
12.25 IL2 STAT1 STAT2 TNF
36
Show member pathways
12.23 IFNG IRAK1 STAT1 TNF
37 12.23 IFNG STAT1 TNF TNFRSF1A
38 12.18 IFNAR2 RIPK1 STAT1 STAT2 TNF TNFRSF1A
39
Show member pathways
12.17 IL2 RIPK1 TNF TNFRSF1A
40
Show member pathways
12.17 IFNG IL10RB IL2 IL2RA STAT1 STAT2
41
Show member pathways
12.17 IFNG IL12RB2 IL2 STAT1 STAT2 TNF
42 12.15 IFNAR2 IFNG STAT1 STAT2 TNF TNFRSF1A
43
Show member pathways
12.13 IFNG IL2 IL2RA STAT1
44
Show member pathways
12.11 HLA-DRB1 IFNG IL12RB2 IL2 IL2RA IRAK1
45 12.06 STAT1 STAT2 TNF
46 12.06 IFNG IL2 IL2RA TNF
47
Show member pathways
12.03 IL2 IL2RA STAT1
48
Show member pathways
12.02 RIPK1 TNF TNFRSF1A
49 12.01 IFNG IL2 TNF
50 11.98 HLA-DPB1 HLA-DRB1 IL2RA TNF

GO Terms for Mumps

Cellular components related to Mumps according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.73 CD46 HLA-DPB1 HLA-DRB1 IFNAR2 IL10RB IL12RB2
2 external side of plasma membrane GO:0009897 9.56 HLA-DRB1 IL12RB2 IL2RA TNF
3 endosome membrane GO:0010008 9.46 HLA-DPB1 HLA-DRB1 IRAK1 RIPK1
4 MHC class II protein complex GO:0042613 9.32 HLA-DPB1 HLA-DRB1
5 cell surface GO:0009986 9.1 CD46 HLA-DPB1 HLA-DRB1 IL2RA TNF TNFRSF1A

Biological processes related to Mumps according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.93 IL2 IL2RA RIPK1 TNF
2 cell surface receptor signaling pathway GO:0007166 9.91 IFNAR2 IFNG IL12RB2 IL2RA TNFRSF1A
3 immune response GO:0006955 9.91 HLA-DPB1 HLA-DRB1 IFNG IL10RB IL2 IL2RA
4 positive regulation of protein phosphorylation GO:0001934 9.9 IFNG IL2 RIPK1 TNF
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.89 IRAK1 RIPK1 TNF TNFRSF1A
6 viral process GO:0016032 9.87 CD46 HLA-DRB1 IRAK1 RIPK1 STAT1 STAT2
7 response to virus GO:0009615 9.86 IFNAR2 IFNG TNF
8 negative regulation of inflammatory response GO:0050728 9.85 IL2 IL2RA TNFRSF1A
9 positive regulation of inflammatory response GO:0050729 9.83 IL2 TNF TNFRSF1A
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 IFNG IL2 TNFRSF1A
11 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.8 RIPK1 TNF TNFRSF1A
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.78 IRAK1 STAT1 TNF
13 tumor necrosis factor-mediated signaling pathway GO:0033209 9.78 RIPK1 STAT1 TNF TNFRSF1A
14 extrinsic apoptotic signaling pathway GO:0097191 9.76 IFNG RIPK1 TNF
15 positive regulation of T cell proliferation GO:0042102 9.76 CD46 HLA-DPB1 IL2 IL2RA
16 defense response to virus GO:0051607 9.73 IFNAR2 IFNG IL10RB IRF2 STAT1 STAT2
17 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.72 RIPK1 TNF TNFRSF1A
18 positive regulation of interferon-gamma production GO:0032729 9.71 HLA-DPB1 IL12RB2 IL2 TNF
19 JAK-STAT cascade GO:0007259 9.7 IFNAR2 STAT1 STAT2
20 positive regulation of T cell differentiation GO:0045582 9.69 IL2 IL2RA
21 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.69 IFNG TNF
22 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.68 HLA-DPB1 HLA-DRB1
23 inflammatory response to antigenic stimulus GO:0002437 9.67 HLA-DRB1 IL2RA
24 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.67 IFNG STAT1
25 positive regulation of regulatory T cell differentiation GO:0045591 9.67 CD46 IL2
26 regulation of regulatory T cell differentiation GO:0045589 9.67 IFNG IL2 IL2RA
27 interleukin-2-mediated signaling pathway GO:0038110 9.66 IL2 IL2RA
28 interleukin-35-mediated signaling pathway GO:0070757 9.66 IL12RB2 STAT1
29 positive regulation of ceramide biosynthetic process GO:2000304 9.65 TNF TNFRSF1A
30 positive regulation of programmed cell death GO:0043068 9.65 RIPK1 TNF
31 response to interferon-beta GO:0035456 9.64 IFNAR2 STAT1
32 regulation of establishment of endothelial barrier GO:1903140 9.63 TNF TNFRSF1A
33 necroptotic signaling pathway GO:0097527 9.62 RIPK1 TNF
34 negative regulation of lymphocyte proliferation GO:0050672 9.61 IL2 IL2RA
35 death-inducing signaling complex assembly GO:0071550 9.61 RIPK1 TNF TNFRSF1A
36 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.58 IFNG TNF
37 regulation of T cell homeostatic proliferation GO:0046013 9.57 IL2 IL2RA
38 interferon-gamma-mediated signaling pathway GO:0060333 9.55 HLA-DPB1 HLA-DRB1 IFNG IRF2 STAT1
39 positive regulation of vitamin D biosynthetic process GO:0060557 9.54 IFNG TNF
40 type I interferon signaling pathway GO:0060337 9.35 IFNAR2 IRAK1 IRF2 STAT1 STAT2
41 cytokine-mediated signaling pathway GO:0019221 9.32 IFNAR2 IL10RB IL12RB2 IL2 IL2RA IRAK1
42 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 IL2 IRF2 RIPK1 STAT1 TNF TNFRSF1A
43 immune system process GO:0002376 10.03 CD46 HLA-DPB1 HLA-DRB1 IL2 IL2RA IRAK1

Molecular functions related to Mumps according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin-like protein ligase binding GO:0044389 8.62 STAT1 STAT2

Sources for Mumps

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....